Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.40 |
| ▸ | SCN1A | P35498 | 2/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 9/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HRH1 | P35367 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1668513 | 0.93 | SCN1A (0.40) | SCN8ASCN1AENPP2RORCNPY5R | |
| SCHEMBL1668845 | 0.86 | SCN1A (0.40) | SCN8ASCN1AENPP2RORCNPY5R | |
| SCHEMBL12198403 | 0.85 | SCN1A (0.36) | SCN8ASCN1ALMNADRD2HTR2A | |
| SCHEMBL1668932 | 0.81 | FPR2 (0.36) | RORCNPY5RFPR2PROKR1IDO1 | |
| SCHEMBL1668609 | 0.80 | FPR2 (0.37) | SCN8ASCN1ARORCNPY5RFPR2 | |
| SCHEMBL1668540 | 0.80 | IDO1 (0.39) | RORCNPY5RFPR2PROKR1IDO1 | |
| SCHEMBL1668410 | 0.79 | KDM4E (0.49) | RORCLMNAKMT2A | |
| SCHEMBL1669079 | 0.79 | LMNA (0.38) | RORCNPY5RFPR2PROKR1IDO1 | |
| SCHEMBL1668891 | 0.79 | GPR119 (0.48) | RORCNPY5RIDO1LMNAKMT2A | |
| SCHEMBL1668473 | 0.79 | SCN1A (0.40) | SCN8ASCN1AENPP2RORCNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575168-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2013-11-05 | — | — | US | claimed |
| EP-2486033-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2012-08-15 | — | — | EP | claimed |
| US-20110245220-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-06 | — | — | US | claimed |
| WO-2011044001-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-04-14 | — | — | WO | claimed |
| US-8575168-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2013-11-05 | — | — | US | disclosed |
| US-8575168-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2013-11-05 | — | — | US | disclosed |
| EP-2486033-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2012-08-15 | — | — | EP | disclosed |
| US-20110245220-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-06 | — | — | US | disclosed |
| WO-2011044001-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245220-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | SCN8A 2135/4885SCN1A 1500/4885ENPP2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.